BRAF V600 Mutations in Solid Tumors Market: By Tumor Type, Non-Small Cell Lung Cancer, and Others), Diagnostic Method, Immunohistochemistry, and Polymerase Chain Reaction ), Treatment Type, and Geography and Forecast to 2030

BRAF V600 Mutations in Solid Tumors Market Size, Share, Growth, Trends, and Global Industry Analysis: By Tumor Type (Melanoma, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC), and Others), Diagnostic Method (Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), and Polymerase Chain Reaction (PCR)), Treatment Type (BRAF Inhibitors, Combination Therapies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and MEA) and Forecast to 2030

BRAF V600 Mutations in Solid Tumors Market size was valued at US$ X million in 2023 and is poised to grow at a CAGR of x% from 2024 - 2030. The BRAF V600 Mutations in Solid Tumors market is a battlefield of innovation, aiming to combat tumors harboring this specific genetic alteration. Advancements in diagnostic tools like next-generation sequencing (NGS) enable more accurate and comprehensive detection of BRAF V600 mutations, leading to earlier identification and treatment initiation. Also, increased educational efforts aimed at both healthcare professionals and the public regarding BRAF mutations are raising awareness of these genetic alterations and the availability of targeted therapies. In addition, the growing emphasis on precision medicine, tailoring treatments to a patient's specific genetic makeup, highlights the importance of BRAF V600 mutation testing for determining the most effective course of therapy. BRAF inhibitor drugs and combination therapies specifically target the BRAF protein with the V600 mutation, demonstrating improved efficacy compared to traditional therapies in many cases. Ongoing clinical trials for new BRAF inhibitor drugs and combination therapies with different mechanisms of action are yielding promising results, offering hope for even more effective treatments in the future.

Moreover, targeted therapies can offer a less toxic and debilitating treatment experience compared to traditional therapies like chemotherapy, potentially improving patient quality of life. As the cost of NGS decreases and its availability increases, it is becoming a more widely used diagnostic tool, leading to the identification of more BRAF V600 mutation-positive tumors and driving market growth. Furthermore, the healthcare sector is shifting towards a value-based care model, where reimbursement is tied to patient outcomes. This incentivizes the use of targeted therapies that demonstrate improved efficacy and survival rates. Also, regulatory bodies are increasingly approving BRAF inhibitor drugs and combination therapies based on robust clinical data. Additionally, reimbursement pathways are being established to ensure patient access to these potentially life-saving treatments. However, BRAF inhibitor drugs and combination therapies are often very expensive, creating a significant financial burden for patients and healthcare systems. This can limit patient access to these potentially life-saving treatments.

 

Recent Market Developments:

  • In July 2022, The Food and Drug Administration (FDA) approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of people with nearly any type of advanced solid tumor that has a specific mutation in a gene called BRAF.
  • In June, 2022, Novartis announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Tafinlar + Mekinist is the first and only BRAF/MEK inhibitor to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types, and it is the only BRAF/MEK inhibitor approved for use in pediatric patients.

BRAF V600 Mutations in Solid Tumors Market Summary

Study Period

2024 - 2030

Base Year

2023

CAGR

x%

Largest Market

North America

Fastest Growing Market

Asia pacific

BRAF V600 Mutations in Solid Tumors Market Dynamics

BRAF V600 mutations are present in a significant percentage of various cancers, and there remains a significant unmet medical need for effective treatments, particularly for patients who do not respond well to traditional therapies. In addition, targeted therapies offer the potential for improved patient outcomes, including increased progression-free survival rates and overall survival rates. This translates to a longer lifespan and better quality of life for patients with BRAF V600 mutation-positive tumors which propels the market expansion. Moreover, the significant potential of BRAF inhibitor drugs and combination therapies is attracting continued investment in research and development. This fuels the discovery of new drugs, improved treatment regimens, and a deeper understanding of BRAF mutations further drives the market growth.

 

BRAF V600 Mutations in Solid Tumors Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024 - 2030

Market CAGR

x%

Tumor Type

  • Melanoma
  • Colorectal Cancer (CRC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Others

By Diagnostic Method

  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)

By Treatment Type

  • BRAF Inhibitors
  • Combination Therapies
  • Others

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

Download Free Sample Report

Frequently Asked Questions

The Asia Pacific is the fastest growing region in the BRAF V600 Mutations in Solid Tumors Market.

The North America dominates the BRAF V600 Mutations in Solid Tumors market.

The leading players in the BRAF V600 Mutations in Solid Tumors Market are Roche, Pfizer, Bayer, Novartis, Exelixis, AstraZeneca, Daiichi Sankyo, Debiopharm Group, Bristol-Myers Squibb, and Eli Lilly and Company.

Historic years considered for the market study are 2019 to 2022, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global BRAF V600 Mutations in Solid Tumors Market Introduction
2.1. Global BRAF V600 Mutations in Solid Tumors Market - Taxonomy
2.2. Global BRAF V600 Mutations in Solid Tumors Market - Definitions
2.2.1. Tumor Type
2.2.2. Treatment Method
2.2.3. BRAF Mutation Status
2.2.4. End-User
2.2.5. Region
3. Global BRAF V600 Mutations in Solid Tumors Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global BRAF V600 Mutations in Solid Tumors Market By Tumor Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
4.1. Melanoma
4.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Colorectal Cancer
4.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
4.3. Lung Cancer
4.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.3.3. Market Opportunity Analysis
4.4. Thyroid Cancer
4.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.4.3. Market Opportunity Analysis
4.5. Other Solid Tumor Types
4.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.5.3. Market Opportunity Analysis
5. Global BRAF V600 Mutations in Solid Tumors Market By Treatment Method, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Targeted Therapies
5 1 1 Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immunotherapy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Combination Therapies
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Surgery
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Radiation Therapy
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global BRAF V600 Mutations in Solid Tumors Market By BRAF Mutation Status, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. BRAF V600E
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. BRAF V600K
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Other BRAF Mutations
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global BRAF V600 Mutations in Solid Tumors Market By End-User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Treatment Centers
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Clinics
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Research Institutions
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global BRAF V600 Mutations in Solid Tumors Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. MEA
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global BRAF V600 Mutations in Solid Tumors Market - Opportunity Analysis Index, By Treatment Method, Tumor Type, BRAF Mutation Status, End-User, , , , and Region, 2024 - 2030
9. North America BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1. Melanoma
9.1.2. Colorectal Cancer
9.1.3. Lung Cancer
9.1.4. Thyroid Cancer
9.1.5. Other Solid Tumor Types
9.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1. Targeted Therapies
9.2.2. Chemotherapy
9.2.3. Immunotherapy
9.2.4. Combination Therapies
9.2.5. Surgery
9.2.6. Radiation Therapy
9.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1. BRAF V600E
9.3.2. BRAF V600K
9.3.3. Other BRAF Mutations
9.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1. Hospitals
9.4.2. Cancer Treatment Centers
9.4.3. Clinics
9.4.4. Research Institutions
9.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.5.1. USA
9.5.2. Canada
10. Europe BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1. Melanoma
10.1.2. Colorectal Cancer
10.1.3. Lung Cancer
10.1.4. Thyroid Cancer
10.1.5. Other Solid Tumor Types
10.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1. Targeted Therapies
10.2.2. Chemotherapy
10.2.3. Immunotherapy
10.2.4. Combination Therapies
10.2.5. Surgery
10.2.6. Radiation Therapy
10.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1. BRAF V600E
10.3.2. BRAF V600K
10.3.3. Other BRAF Mutations
10.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1. Hospitals
10.4.2. Cancer Treatment Centers
10.4.3. Clinics
10.4.4. Research Institutions
10.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
11. Asia Pacific BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1. Melanoma
11.1.2. Colorectal Cancer
11.1.3. Lung Cancer
11.1.4. Thyroid Cancer
11.1.5. Other Solid Tumor Types
11.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1. Targeted Therapies
11.2.2. Chemotherapy
11.2.3. Immunotherapy
11.2.4. Combination Therapies
11.2.5. Surgery
11.2.6. Radiation Therapy
11.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1. BRAF V600E
11.3.2. BRAF V600K
11.3.3. Other BRAF Mutations
11.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1. Hospitals
11.4.2. Cancer Treatment Centers
11.4.3. Clinics
11.4.4. Research Institutions
11.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.5.1. China
11.5.2. Japan
11.5.3. South Korea
11.5.4. India
11.5.5. Rest of APAC
12. Latin America BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1. Melanoma
12.1.2. Colorectal Cancer
12.1.3. Lung Cancer
12.1.4. Thyroid Cancer
12.1.5. Other Solid Tumor Types
12.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1. Targeted Therapies
12.2.2. Chemotherapy
12.2.3. Immunotherapy
12.2.4. Combination Therapies
12.2.5. Surgery
12.2.6. Radiation Therapy
12.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1. BRAF V600E
12.3.2. BRAF V600K
12.3.3. Other BRAF Mutations
12.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1. Hospitals
12.4.2. Cancer Treatment Centers
12.4.3. Clinics
12.4.4. Research Institutions
12.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Argentina
12.5.4. Rest of Latin America
13. MEA BRAF V600 Mutations in Solid Tumors Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Tumor Type Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1. Melanoma
13.1.2. Colorectal Cancer
13.1.3. Lung Cancer
13.1.4. Thyroid Cancer
13.1.5. Other Solid Tumor Types
13.2. Treatment Method Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1. Targeted Therapies
13.2.2. Chemotherapy
13.2.3. Immunotherapy
13.2.4. Combination Therapies
13.2.5. Surgery
13.2.6. Radiation Therapy
13.3. BRAF Mutation Status Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1. BRAF V600E
13.3.2. BRAF V600K
13.3.3. Other BRAF Mutations
13.4. End-User Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1. Hospitals
13.4.2. Cancer Treatment Centers
13.4.3. Clinics
13.4.4. Research Institutions
13.5. Country Analysis, 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Roche
14.2.2. Pfizer
14.2.3. Novartis
14.2.4. Bristol-Myers Squibb
14.2.5. Eli Lilly and Company
14.2.6. Debiopharm Group
14.2.7. Bayer
14.2.8. AstraZeneca
14.2.9. Exelixis
14.2.10. Daiichi Sankyo
15. Research Methodology
16. Key Assumptions and Acronyms

Key Market Players

  • Roche
  • Pfizer
  • Bayer
  • Novartis
  • Exelixis
  • AstraZeneca
  • Daiichi Sankyo
  • Debiopharm Group
  • Bristol-Myers Squibb
  • Eli Lilly and Company

Related Industry Reports